PF-Atlas › Clinical Trials › NCT02036970
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension - LARIAT
Bardoxolone methyl · Phase 2
Registry ID
NCT02036970
Phase
Phase 2
Status
Completed
Drug / intervention
Bardoxolone methyl
Sponsor
Biogen
Start
2014-05-31
Enrollment
166
Locations
32
About this trial
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02036970 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.